Search Share Prices
Allergy Therapeutics releases 'exciting' dust-mite immunotherapy data
Biotechnology company Allergy Therapeutics announced positive new data on its wholly-owned modified house-dust mite subcutaneous immunotherapy on Tuesday.
The AIM-traded firm was presenting the data at the 37th Annual Congress of the European Academy of Allergy and Clinical Immunology in Munich.
It said its modified house-dust mite product sold through a Named Patient Program in Spain was the precursor to the modified house-dust mite + MPL product currently in Phase I, as announced in February last year.
In the observational study conducted in 10 sites across Spain, 141 patients were evaluated and demonstrated a 43% decrease in combined symptom medication score when compared with baseline after one year.
Allergy Therapeutics said that in addition, in a subgroup of asthmatic subjects, 16.7% of patients were observed with moderate persistent asthma at one year compared with 50.9% at baseline.
No patients presented with serious adverse events, no patients had to stop treatment due to any adverse event.
Allergy Therapeutics also presented a series of poster presentations at EAACI with key highlights including an overview of the early-phase pre-clinical developments for the group's planned recombinant peanut vaccine, and a discussion of the results of a non-interventional study investigating rapid up-dosing of tree sublingual immunotherapy.
Other events held by the Group at EAACI included a satellite symposium entitled 'adjuvants through the ages', which the board said provided a summary of how adjuvant technologies had evolved and how Allergy Therapeutics was "spearheading" the design and testing of allergen-specific immunotherapies.
"We are excited to be sharing our latest research at EAACI, demonstrating the breadth of our unique allergen immunotherapy company," said CEO Manuel Llobet.
"The positive new data on our modified house-dust mite immunotherapy and our recent announcement on the success of our Grass G205 dose-finding clinical study confirms that our novel allergen-specific immunotherapies are formulated to the optimal strength, and we believe Allergy Therapeutics has the potential to transform allergy treatment with optimised-dose, well-characterised, aluminium-free, convenient products."